Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Jiangxi Rimag Group Co's ROE % or its related term are showing as below:
HKSE:02522'
s ROE % Range Over the Past 10 Years
Min: -28.42 Med: 0.03 Max: 3.43
Current: 0.22
During the past 5 years, Jiangxi Rimag Group Co's highest ROE % was 3.43%. The lowest was -28.42%. And the median was 0.03%.
HKSE:02522's ROE % is ranked worse than 69.4% of 621
companies
in the Healthcare Providers & Services industry
Industry Median: 6.01
vs HKSE:02522: 0.22
Jiangxi Rimag Group Co (HKSE:02522) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Jiangxi Rimag Group Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangxi Rimag Group Co ROE % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Jiangxi Rimag Group Co's ROE % distribution charts can be found below:
* The bar in red indicates where Jiangxi Rimag Group Co's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Jiangxi Rimag Group Co (HKSE:02522) has a ROE % of -1.42% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Jiangxi Rimag Group Co and its competitors. According to the industry distribution chart, Jiangxi Rimag Group Co ranks #431 out of 621 companies in the Healthcare Providers & Services industry, placing it in the top 69.4%.
Is Jiangxi Rimag Group Co's ROE % too high?
Jiangxi Rimag Group Co's current ROE % is -1.42%. Based on the distribution chart, Jiangxi Rimag Group Co ranks #431 out of 621 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Jiangxi Rimag Group Co has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Jiangxi Rimag Group Co's ROE % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Jiangxi Rimag Group Co ranks #431 out of 621 companies for ROE %. This places Jiangxi Rimag Group Co in the lower half of its industry. The industry median ROE % is 6.01. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Healthcare Providers & Services company?
The median ROE % among Healthcare Providers & Services companies is 6.01, based on 621 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Jiangxi Rimag Group Co and its competitors. For the Healthcare Providers & Services industry, the median ROE % is 6.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangxi Rimag Group Co's current ROE % is -1.42%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangxi Rimag Group Co stock overvalued right now?
Jiangxi Rimag Group Co (HKSE:02522) has a current ROE % of -1.42%. The current ROE % is -1.42%. Jiangxi Rimag Group Co's overall GF Score™ is 14/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Jiangxi Rimag Group Co (HKSE:02522), the current ROE % is -1.42% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Jiangxi Rimag Group Co Ltd is a medical group specializing in medical imaging in China. The company generates revenue through these segments: Imaging Center Services, Imaging Solution Services, and Digital-intelligence services. The Imaging Center Services include examination and diagnostic services to patients and other healthcare consumers via its flagship imaging centers, such as MRI, CT, PET, X-ray, ultrasound and mammography. Majority of the revenue comes from Imaging center services. Geographically, the company operates in Chinese Mainland and Overseas (including Hong Kong and Macau). It generates maximum revenue from Chinese Mainland.
14GF Score
Get the complete analysis for HKSE:02522
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02522 has been successfully added to your 
